Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

Charlotta Hedner; Lena Tran; David Borg; Björn Nodin; Karin Jirström; Jakob Eberhard

doi:10.1111/his.12744

Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

Charlotta Hedner, Lena Tran, David Borg, Björn Nodin, Karin Jirström, Jakob Eberhard

Tumörmikromiljö

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Sammanfattning

Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.

Originalspråk	engelska
Tidskrift	Histopathology
Tidigt onlinedatum	2015 maj 27
DOI	https://doi.org/10.1111/his.12744
Status	Published - 2015

Ämnesklassifikation (UKÄ)

Cell- och molekylärbiologi

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

Tillgång till dokument

10.1111/his.12744

http://www.ncbi.nlm.nih.gov/pubmed/26016514?dopt=Abstract

1 Doktorsavhandling (sammanläggning)

Prognostic biomarkers in upper gastrointestinal adenocarcinoma
HEDNER, C., 2016, Lund: Lund University: Faculty of Medicine. 78 s.
Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)

Öppen tillgång
Fil

Citera det här

@article{2925b5f360804594a782ed02f25df724,

title = "Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.",

abstract = "Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.",

author = "Charlotta Hedner and Lena Tran and David Borg and Bj{\"o}rn Nodin and Karin Jirstr{\"o}m and Jakob Eberhard",

year = "2015",

doi = "10.1111/his.12744",

language = "English",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

AU - Hedner, Charlotta

AU - Tran, Lena

AU - Borg, David

AU - Nodin, Björn

AU - Jirström, Karin

AU - Eberhard, Jakob

PY - 2015

Y1 - 2015

N2 - Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.

AB - Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.

U2 - 10.1111/his.12744

DO - 10.1111/his.12744

M3 - Article

C2 - 26016514

SN - 0309-0167

JO - Histopathology

JF - Histopathology

ER -

Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

Sammanfattning

Ämnesklassifikation (UKÄ)

FN:s Globala mål

Tillgång till dokument

Fingeravtryck

Forskningsoutput

Prognostic biomarkers in upper gastrointestinal adenocarcinoma

Citera det här